Engineered E. coli for High-Titer Biopolymers with Basal Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant production of spider silk proteins (spidroins) and elastin-like peptides (ELPs) is hindered by low titers and high production costs due to issues like plasmid instability, inclusion body formation, low solubility, and transcriptional errors, making it impractical for commercial-scale applications.
Innovation Solution
A modified E. coli strain with specific mutations in stress-response genes and a controlled promoter system is used to inhibit basal expression, combined with an expression vector, to produce high titers of disordered polypeptides such as spidroins and ELPs, minimizing toxicity and maintaining plasmid stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If recombinant production is used to produce spidroins and ELPs, then production scalability is improved, but production titer remains low and costs remain high
Solution Approach 1:
The patent modifies multiple parameters of the E. coli host system including genomic mutations in stress-response genes (rpoS, sigma factors), plasmid copy number control, and expression timing parameters to optimize production titer while maintaining scalability
Solution Approach 2:
The patent uses copy number controlled plasmids to replicate and amplify the spidroin/ELP gene sequences within the bacterial host, enabling high-level protein production through controlled genomic copying rather than direct chromosomal integration
2Productivity
If basal expression is not inhibited, then protein production begins immediately, but toxicity increases and plasmid stability decreases
Solution Approach 1:
The patent implements preliminary control mechanisms where the promoter system is designed to remain inactive during critical growth phases, and only activates at predetermined stages when the bacterial culture reaches optimal density and physiological state for high-level expression
Solution Approach 2:
The patent employs feedback control through stress-response gene mutations that sense cellular physiological state and regulate expression levels accordingly, preventing expression under conditions that would cause toxicity or plasmid loss while enabling expression when conditions are favorable
3Speed
If expression is not controlled, then production speed increases, but inclusion body formation increases and solubility decreases
Solution Approach 1:
The patent implements dynamic control of expression where the system transitions from no expression to controlled expression to high-level expression based on real-time cellular conditions, allowing the bacteria to maintain normal folding machinery during rapid production phases
Solution Approach 2:
The patent uses periodic induction strategies where expression is activated in controlled pulses or phases rather than continuously, allowing cellular chaperone systems to process proteins between expression bursts and prevent aggregation
Data Source
AI summary
Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.